What's Wrong With UnitedHealth Stock?

Source The Motley Fool

Key Points

  • UnitedHealth reported earnings recently, which beat on the bottom line but missed on revenue.

  • The company's guidance is soft for the year ahead as management expects a decline.

  • The Trump administration has proposed just a nominal increase in Medicare Advantage rates for 2027.

  • 10 stocks we like better than UnitedHealth Group ›

UnitedHealth Group (NYSE: UNH) is a stock that looks to be in deep trouble. As of the end of January, it was already down 13% in 2026. And that's after an already brutal year in 2025, when it fell 35% in value. Investors have been dumping the stock in droves, as things appear to be going from bad to worse.

The company recently released its latest quarterly results, which only exacerbated concerns about its future and whether this is still a good business to invest in. Here's why UnitedHealth stock seems to be in an endless free fall these days, and whether you should consider taking a chance on it.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

Frustrated investor looking at stocks.

Image source: Getty Images.

What's weighing down UnitedHealth stock?

UnitedHealth reported its fourth-quarter results last week, and they technically weren't all that bad. The company beat expectations on the bottom line as its adjusted earnings per share came in at $2.11 versus the $2.10 that analysts were projecting. The company's top line was a little weak, however, totaling $113.2 billion, which was slightly lower than the $113.82 billion that Wall Street was looking for.

It was a slight miss on revenue, but the bigger concern is that the future may not be all that much more promising for UnitedHealth. The Trump administration is proposing that rates are flat for Medicare Advantage in 2027, which is bad news not only for UnitedHealth, but other health insurance companies as well. Analysts were expecting rates to increase by at least 4%, while the government proposal calls for a rate increase of just 0.09%.

This is already as UnitedHealth is struggling to grow in 2026. For the current year, it forecasts revenue to be around $439 billion, which would represent a year-over-year decline of 2%.

A recovery may not be coming this year

There's a lot of attention these days on high healthcare costs, which is why I'm not optimistic that UnitedHealth's stock will experience a quick turnaround. For years, this has been a strong growth stock to own as the company has been doing well on both its top and bottom lines. That simply may not be the case anymore, at least in the short term. UnitedHealth has been struggling with rising utilization rates and higher medical costs, and now, it's looking as though it will be difficult to generate much revenue growth as well.

All in all, it doesn't paint a terribly exciting picture for the healthcare stock. At the very least, you'll need to be extremely patient with it, because there's no reason, unfortunately, to expect things to get better for UnitedHealth in the near future.

Should you buy stock in UnitedHealth Group right now?

Before you buy stock in UnitedHealth Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $446,319!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,137,827!*

Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 3, 2026.

David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Ethereum (ETH) Price Closes Above $3,900 — Is a New All-Time High Possible Before 2024 Ends?Once again, the price of Ethereum (ETH) has risen above $3,900. This bounce has hinted at a further price increase for the altcoin before the end of the year.
Author  Beincrypto
Dec 17, 2024
Once again, the price of Ethereum (ETH) has risen above $3,900. This bounce has hinted at a further price increase for the altcoin before the end of the year.
placeholder
Markets in 2026: Will gold, Bitcoin, and the U.S. dollar make history again? — These are how leading institutions thinkAfter a turbulent 2025, what lies ahead for commodities, forex, and cryptocurrency markets in 2026?
Author  Insights
Dec 25, 2025
After a turbulent 2025, what lies ahead for commodities, forex, and cryptocurrency markets in 2026?
placeholder
Bitcoin Faces Risk of Deeper Losses as Price Action Echoes Past Bear MarketsBitcoin price targets remain bearish as it struggles near multi-month lows, influenced by historical bear market trends.
Author  Mitrade
Feb 02, Mon
Bitcoin price targets remain bearish as it struggles near multi-month lows, influenced by historical bear market trends.
placeholder
Analyst Flags XRP as Market’s ‘Best Risk/Reward’ Play as Token Tests Critical $1.60 SupportCrypto analyst Scott Melker identifies a prime risk/reward setup for XRP as it tests key support at $1.60, offering a tight stop-loss against potential upside targets near $2.00.
Author  Mitrade
21 hours ago
Crypto analyst Scott Melker identifies a prime risk/reward setup for XRP as it tests key support at $1.60, offering a tight stop-loss against potential upside targets near $2.00.
placeholder
Bitcoin Reaches ‘Fire-Sale’ Valuations as ETF Outflows Jump, Says BitwiseBitcoin’s two-year rolling MVRV z-score has dropped to its lowest level ever, pointing to extreme undervaluation.
Author  Mitrade
17 hours ago
Bitcoin’s two-year rolling MVRV z-score has dropped to its lowest level ever, pointing to extreme undervaluation.
goTop
quote